Cassiopea Announces Very Positive Top-Line Phase 3 Results for Winlevi® (Clascoterone) cream in Treating Acne
Cassiopea SpA, a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced that top line results from two pivotal phase 3 clinical trials for its topical anti-androgen Winlevi® cream 1% (Clascoterone) demonstrated highly statistically significant improvements for all primary clinical end points.and differentiated medical dermatology products, today announced that top line results from two pivotal phase 3 clinical trials for its topical anti-androgen Winlevi® cream 1% (Clascoterone) demonstrated highly statistically significant improvements for all primary clinical end points.